FNY Investment Advisers LLC Buys 42,298 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

FNY Investment Advisers LLC lifted its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 125.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,966 shares of the company’s stock after acquiring an additional 42,298 shares during the period. FNY Investment Advisers LLC’s holdings in Ginkgo Bioworks were worth $745,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. AQR Capital Management LLC bought a new position in shares of Ginkgo Bioworks during the second quarter worth $3,391,000. Renaissance Technologies LLC acquired a new stake in Ginkgo Bioworks in the 2nd quarter valued at approximately $2,128,000. XTX Topco Ltd bought a new stake in Ginkgo Bioworks in the 2nd quarter valued at approximately $312,000. Mackenzie Financial Corp acquired a new position in Ginkgo Bioworks during the 2nd quarter worth approximately $251,000. Finally, Erste Asset Management GmbH acquired a new stake in shares of Ginkgo Bioworks in the third quarter valued at approximately $4,075,000. Institutional investors and hedge funds own 78.63% of the company’s stock.

Ginkgo Bioworks Trading Down 9.7 %

Shares of DNA opened at $8.83 on Tuesday. The company has a market cap of $507.54 million, a P/E ratio of -0.68 and a beta of 1.09. The company has a 50-day moving average price of $9.18. Ginkgo Bioworks Holdings, Inc. has a one year low of $5.26 and a one year high of $64.40.

Wall Street Analyst Weigh In

Separately, TD Cowen increased their target price on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, September 20th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $4.58.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.